Pharmacological inhibition of the transcription factor PU.1 in leukemia

The transcription factor PU.1 is often impaired in patients with acute myeloid leukemia (AML). Here, we used AML cells that already had low PU.1 levels and further inhibited PU.1 using either RNA interference or, to our knowledge, first-in-class small-molecule inhibitors of PU.1 that we developed sp...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Invest
Main Authors: Antony-Debré, Iléana, Paul, Ananya, Leite, Joana, Mitchell, Kelly, Kim, Hye Mi, Carvajal, Luis A., Todorova, Tihomira I., Huang, Kenneth, Kumar, Arvind, Farahat, Abdelbasset A., Bartholdy, Boris, Narayanagari, Swathi-Rao, Chen, Jiahao, Ambesi-Impiombato, Alberto, Ferrando, Adolfo A., Mantzaris, Ioannis, Gavathiotis, Evripidis, Verma, Amit, Will, Britta, Boykin, David W., Wilson, W. David, Poon, Gregory M.K., Steidl, Ulrich
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Clinical Investigation 2017
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5707147/
https://ncbi.nlm.nih.gov/pubmed/29083320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI92504
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים